Semaglutide
GLP-1 Receptor Agonist
Semaglutide is a GLP-1 receptor agonist that helps regulate appetite, slow gastric emptying, and support sustainable weight loss when combined with diet and exercise.
The Science
What is Semaglutide?
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist that mimics a hormone naturally produced in the gut after eating. This hormone signals the brain to register satiety, reduces appetite, and slows the rate at which food leaves the stomach.
Originally developed for type 2 diabetes management, semaglutide demonstrated such significant weight loss effects that the FDA approved it specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition.
Laboratory Observations
Key Observed Effects of Semaglutide
Significant Weight Loss
Clinical trials showed participants lost an average of 15% of their body weight over 68 weeks—significantly more than diet and exercise alone.
Appetite Regulation
Works with the subject’s natural hunger signals to reduce cravings and support feelings of satisfied with smaller portions.
Metabolic Improvements
May improve blood sugar control, blood pressure, and cholesterol levels—benefits that extend beyond weight loss alone.
Cardiovascular Benefits
Studies indicate reduced risk of major cardiovascular events in adults with obesity and established heart disease.
Sustainable Results
When combined with lifestyle changes, helps establish healthier eating patterns that can be maintained long-term.
Mechanism of Action
The GLP-1 Mechanism
Semaglutide works through multiple pathways to support sustainable weight loss.
Appetite Reduction
Activates receptors in the brain that control hunger and satiety, supporting feelings of satisfied with smaller portions and reducing cravings between meals.
Slower Gastric Emptying
Delays stomach emptying so food stays in the system longer. This prolongs feelings of fullness and helps prevent overeating at subsequent meals.
Blood Sugar Regulation
Stimulates insulin release when blood sugar rises and reduces glucagon secretion, helping maintain stable glucose levels throughout the day.
Research-Only Notice
Semaglutide is categorized by the FDA as for research-purposes-only. It is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease. The information above summarizes effects observed in laboratory studies to date and is provided strictly for scientific and educational reference.